PMID- 12939715
OWN - NLM
STAT- MEDLINE
DCOM- 20030924
LR  - 20191107
IS  - 0093-7754 (Print)
IS  - 0093-7754 (Linking)
VI  - 30
IP  - 4
DP  - 2003 Aug
TI  - HLA class II antibodies in the treatment of hematologic malignancies.
PG  - 465-75
AB  - Promising results have suggested human leukocyte antigen (HLA) class II as 
      potential target for antibody-based lymphoma therapy. Thus, antibodies against 
      HLA class II induced apoptosis in vitro, as well as complement-dependent 
      cytotoxicity (CDC) and effector cell-mediated cytotoxicity (ADCC). Furthermore, 
      animal models demonstrated strong antitumor effects in vivo. Importantly, early 
      clinical studies with antibodies Lym-1 or Hu1D10, both against HLA-DR variants, 
      suggested therapeutic potential. However, the increased risk of serious toxicity 
      may require an improved understanding of the clinically relevant mechanisms of 
      action of HLA class II-directed antibodies, which may then allow generation of 
      optimized antibody constructs to achieve optimal therapeutic efficacy.
FAU - Dechant, Michael
AU  - Dechant M
AD  - Department of Medicine III, University Erlangen-Nuremberg, Germany.
FAU - Bruenke, Joerg
AU  - Bruenke J
FAU - Valerius, Thomas
AU  - Valerius T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibody-Dependent Cell Cytotoxicity/immunology
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis/immunology
MH  - Cytotoxicity, Immunologic/immunology
MH  - HLA-DR Antigens/immunology
MH  - Hematologic Neoplasms/*therapy
MH  - Histocompatibility Antigens Class II/*immunology
MH  - Humans
RF  - 95
EDAT- 2003/08/27 05:00
MHDA- 2003/09/25 05:00
CRDT- 2003/08/27 05:00
PHST- 2003/08/27 05:00 [pubmed]
PHST- 2003/09/25 05:00 [medline]
PHST- 2003/08/27 05:00 [entrez]
AID - S0093775403002525 [pii]
AID - 10.1016/s0093-7754(03)00252-5 [doi]
PST - ppublish
SO  - Semin Oncol. 2003 Aug;30(4):465-75. doi: 10.1016/s0093-7754(03)00252-5.